Reports and Briefs

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

2009 Pharmaceutical M&A Overview

An overview of M&A trends for the top 150 global pharmaceutical companies during 2008 and 2009 with discussion of the drivers of recent deals, plus case study analysis of key M&As.

Published By Datamonitor
17 Dec 2009 $11400
Buy
Brief
Brief

2009: A Year of mHealth Buzz, Hype (Analyst Opinion)

A Datamonitor analyst opinion piece on the current state of the mHealth market.

Published By Datamonitor
24 Dec 2009 $150
Buy
Brief
Brief

2010 Guide to the Life Sciences Industry for Technology Providers

Overview of the life sciences industry and key opportunities for technology vendors

Published By Datamonitor
12 Mar 2010 $1895
Buy
Brief
Brief

2010 Trends to Watch: Healthcare Technology

This brief outlines key business issues and technology enablers that are expected to affect the healthcare industry during 2010.

Published By Datamonitor
09 Dec 2009 $1895
Buy
Brief
Brief

2010 Trends to Watch: Knowledge Process Outsourcing

Technology markets are changing fast. This brief is essential reading for you to identify and track the key forces shaping the prospects for your business.

Published By Datamonitor
25 Dec 2009 $1895
Buy
Brief
Brief

2010 Trends to Watch: Pharmaceutical Technology

This brief outlines key business issues and technology enablers that are expected to affect the pharmaceutical industry during 2010.

Published By Datamonitor
09 Dec 2009 $1895
Buy
Report
Report

5EU: Pricing, Reimbursement and Regulatory Update

Datamonitor’s report 5EU: Pricing, Reimbursement, and Regulatory Update provides an overview of developments regarding healthcare reforms, drug regulation, and drug pricing and reimbursement in France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
28 Oct 2011 $1900
Buy
Report
Report

Abbott Laboratories: Company Analysis

Analysis of Abbott's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
08 Aug 2012 $5700
Buy
Report
Report

Accelerating Lead Generation

The number of approvals for new drugs has fallen steadilyin recent years, despite increasing R&D expenditure. Improvements in lead generation essential for companies aiming to avoid expensive compound failures in the later stages of development.

Published By Business Insights
01 Jun 2009 $3835
Buy
Report
Report

Accelerating Lead Generation: Emerging technologies and strategies

'Accelerating Lead Generation: Emerging technologies and strategies' provides an in-depth examination of state-of-the-art technologies for lead generation. This report assesses the potential of new and emerging technologies for improving the quality of drug candidates entering clinical research, and reviews the benefits associated with different approaches to lead generation, including high throughput screening, fragment based drug discovery and virtual screening.

Published By Business Insights
01 Jun 2009 $3835
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.